Portfolio company Firefly Bio was acquired by Johnson & Johnson to advance next-generation oncology innovation.
JUL 29, 2026
Firefly Bio launched with a $94M Series A financing.
FEB 15, 2024
Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders
Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders. Their proprietary platform results in highly specific delivery of degraders to target tissue.